Therapy
Cilta-cel
Ciltacabtagene autoleucel: BCMA-targeting CAR-T with 4-1BB co-stimulatory domain + DUAL BCMA-binding scFv (higher avidity → kills cells with lower BCMA expression; reduces antigen escape).
Also called: ciltacabtagene autoleucel, CARVYKTI, anti-BCMA CAR-T
In short
- 1What it is: a therapy in therapies and applications.
- 2How it connects: acts on 4 and is affected by 1 concepts — mostly 1 receptor, 2 disease, 1 trial.
- 3Where it sits: therapy, trial on the 15-step immune chain.
What it does
CARTITUDE-4 (N=419): cilta-cel vs SoC in 1-3 prior line MM → PFS HR 0.26 (74% reduction in progression/death risk); 12-month PFS 76% vs 49%; ORR 84% vs 67%; one of the largest PFS benefits in any randomised oncology trial.
Its connections at a glance
Each dot is a concept directly linked to Cilta-cel. Colours show the kind of concept.
Sources & evidenceloading…
Loading reviewed sources…
Graph ID I016 · concept status: established. Select any connection above to inspect evidence for that specific link.